p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study.
Date
2023-05-01ICR Author
Author
Köbel, M
Kang, E-Y
Weir, A
Rambau, PF
Lee, C-H
Nelson, GS
Ghatage, P
Meagher, NS
Riggan, MJ
Alsop, J
Anglesio, MS
Beckmann, MW
Bisinotto, C
Boisen, M
Boros, J
Brand, AH
Brooks-Wilson, A
Carney, ME
Coulson, P
Courtney-Brooks, M
Cushing-Haugen, KL
Cybulski, C
Deen, S
El-Bahrawy, MA
Elishaev, E
Erber, R
Fereday, S
AOCS Group,
Fischer, A
Gayther, SA
Barquin-Garcia, A
Gentry-Maharaj, A
Gilks, CB
Gronwald, H
Grube, M
Harnett, PR
Harris, HR
Hartkopf, AD
Hartmann, A
Hein, A
Hendley, J
Hernandez, BY
Huang, Y
Jakubowska, A
Jimenez-Linan, M
Jones, ME
Kennedy, CJ
Kluz, T
Koziak, JM
Lesnock, J
Lester, J
Lubiński, J
Longacre, TA
Lycke, M
Mateoiu, C
McCauley, BM
McGuire, V
Ney, B
Olawaiye, A
Orsulic, S
Osorio, A
Paz-Ares, L
Ramón Y Cajal, T
Rothstein, JH
Ruebner, M
Schoemaker, MJ
Shah, M
Sharma, R
Sherman, ME
Shvetsov, YB
Singh, N
Steed, H
Storr, SJ
Talhouk, A
Traficante, N
Wang, C
Whittemore, AS
Widschwendter, M
Wilkens, LR
Winham, SJ
Benitez, J
Berchuck, A
Bowtell, DD
Candido Dos Reis, FJ
Campbell, I
Cook, LS
DeFazio, A
Doherty, JA
Fasching, PA
Fortner, RT
García, MJ
Goodman, MT
Goode, EL
Gronwald, J
Huntsman, DG
Karlan, BY
Kelemen, LE
Kommoss, S
Le, ND
Martin, SG
Menon, U
Modugno, F
Pharoah, PD
Schildkraut, JM
Sieh, W
Staebler, A
Sundfeldt, K
Swerdlow, AJ
Ramus, SJ
Brenton, JD
Type
Journal Article
Metadata
Show full item recordAbstract
Our objective was to test whether p53 expression status is associated with survival for women diagnosed with the most common ovarian carcinoma histotypes (high-grade serous carcinoma [HGSC], endometrioid carcinoma [EC], and clear cell carcinoma [CCC]) using a large multi-institutional cohort from the Ovarian Tumor Tissue Analysis (OTTA) consortium. p53 expression was assessed on 6,678 cases represented on tissue microarrays from 25 participating OTTA study sites using a previously validated immunohistochemical (IHC) assay as a surrogate for the presence and functional effect of TP53 mutations. Three abnormal expression patterns (overexpression, complete absence, and cytoplasmic) and the normal (wild type) pattern were recorded. Survival analyses were performed by histotype. The frequency of abnormal p53 expression was 93.4% (4,630/4,957) in HGSC compared to 11.9% (116/973) in EC and 11.5% (86/748) in CCC. In HGSC, there were no differences in overall survival across the abnormal p53 expression patterns. However, in EC and CCC, abnormal p53 expression was associated with an increased risk of death for women diagnosed with EC in multivariate analysis compared to normal p53 as the reference (hazard ratio [HR] = 2.18, 95% confidence interval [CI] 1.36-3.47, p = 0.0011) and with CCC (HR = 1.57, 95% CI 1.11-2.22, p = 0.012). Abnormal p53 was also associated with shorter overall survival in The International Federation of Gynecology and Obstetrics stage I/II EC and CCC. Our study provides further evidence that functional groups of TP53 mutations assessed by abnormal surrogate p53 IHC patterns are not associated with survival in HGSC. In contrast, we validate that abnormal p53 IHC is a strong independent prognostic marker for EC and demonstrate for the first time an independent prognostic association of abnormal p53 IHC with overall survival in patients with CCC.
Collections
Subject
TP53
clear cell
endometrioid
high-grade serous carcinoma
ovarian cancer
p53
prognosis
Humans
Female
Tumor Suppressor Protein p53
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Carcinoma, Endometrioid
Research team
Integrative Cancer Epidem
Language
eng
Date accepted
2023-01-11
License start date
2023-05-01
Citation
The Journal of Pathology: Clinical Research, 2023, 9 (3), pp. 208 - 222
Publisher
WILEY
Except where otherwise noted, this item's license is described
as
http://creativecommons.org/licenses/by/4.0/
Related items
Showing items related by title, author, creator and subject.
-
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2,; Hollestelle, A; van der Baan, FH; Berchuck, A; Johnatty, SE; et al. (ACADEMIC PRESS INC ELSEVIER SCIENCE, 2016-05-01)OBJECTIVE: Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3' UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer ... -
Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients.
Vergote, I; Banerjee, S; Gerdes, A-M; van Asperen, C; Marth, C; et al. (2016-12)Traditionally, BRCA genetic testing has been undertaken to identify patients and family members at future risk of developing cancer and patients have been referred for testing based on family history. However, the now ... -
Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study.
Morgan, RD; Clamp, AR; Barnes, BM; Timms, K; Schlecht, H; et al. (BMJ PUBLISHING GROUP, 2023-08-07)OBJECTIVE: Olaparib plus bevacizumab maintenance therapy improves survival outcomes in women with newly diagnosed, advanced, high-grade ovarian cancer with a deficiency in homologous recombination. We report data from the ...